Navigation Links
PDL BioPharma Announces New Licensing Agreement With Eli Lilly
Date:12/21/2009

INCLINE VILLAGE, Nev., Dec. 21 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company (NYSE: LLY) under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details of the licensing agreement were made available.

Lilly currently holds a license to the Queen et al patents with respect to solanezumab, its humanized antibody to beta amyloid which is currently being studied to delay the progression of Alzheimer's disease.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

This press release contains forward-looking statements. As with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that a product will receive regulatory approvals, or that the regulatory approval will be for the indication(s) anticipated by the Company. There is also no guarantee that a product will prove to be commercially successful. PDL undertakes no duty to update forward-looking statements.

SOURCE PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... DUBLIN , Mar 22, 2017 Research ... Packaging Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 7.1% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... Massachusetts , March 22, 2017 ... solutions, announced today that Newton-Wellesley Hospital, a nationally recognized medical ... significant improvement in patient outcomes following continued implementation of its ... overall reduction of 59% in median nurse response time to ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... Segundo, CA (PRWEB) , ... March 23, 2017 ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys ... source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted ...
(Date:3/23/2017)... Jersey (PRWEB) , ... March 23, 2017 , ... ... of herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams ... products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored ... 2pm. All events will be located in the Main West Entrance of The ... Child ID event. No appointment is necessary and each child with a parent or ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... selected HealthiPASS, an innovative patient - centric payment system, to expand its focus ... improvements in the patient financial experience. , “At Ogden Clinic, we are ...
Breaking Medicine News(10 mins):